Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option?

Analytical Cellular Pathology

Volumn 2015, Issue , 2015, Pages

  Fanale, Daniele ^a   Bronte, Giuseppe ^a   Passiglia, Francesco ^a   Calò, Valentina ^a   Castiglia, Marta ^a   Di Piazza, Florinda ^a   Barraco, Nadia ^a   Cangemi, Antonina ^a   Catarella, Maria Teresa ^a   Insalaco, Lavinia ^a   Listì, Angela ^a   Maragliano, Rossella ^a   Massihnia, Daniela ^a   Perez, Alessandro ^a   Toia, Francesca ^a   Cicero, Giuseppe ^a   Bazan, Viviana ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BATABULIN; CEMADOTIN; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; CRYPTOPHYCIN 52; DISCODERMOLIDE; DOLASTATIN; DOLASTATIN 15; ELEUTHEROBIN; EPOTHILONE DERIVATIVE; INDIBULIN; IXABEPILONE; LAULIMALIDE; MIVOBULIN ISETHIONATE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; OMBRABULIN; PSEUDOLARIC ACID B; RHIZOXIN; SOBLIDOTIN; T 900607; TASIDOTIN; UNCLASSIFIED DRUG;

ANAPHASE; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; CANCER THERAPY; CELL CYCLE; CELL PROLIFERATION; HUMAN; METAPHASE; MICROTUBULE; MITOSIS SPINDLE; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; HUMANS; MICROTUBULES; NEOPLASMS;

EID: 84943329644     PISSN: 22107177     EISSN: 22107185     Source Type: Journal    
DOI: 10.1155/2015/690916     Document Type: Review

References (215)

1. L. G.Wang, X.M. Liu,W. Kreis, and D. R. Budman. "The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review". Cancer Chemotherapy, and Pharmacology, vol. 44, no. 5, pp. 355-361, 1999
2. J. J. Vicente, and L.Wordeman. "Mitosis, microtubule dynamics, and the evolution of kinesins". Experimental Cell Research, vol. 334, no. 1, pp. 61-69, 2015
3. A. Desai, and T. J. Mitchison. "Microtubule polymerization dynamics". Annual Review of Cell, and Developmental Biology, vol. 13, pp. 83-117, 1997
4. H. Bringmann, G. Skiniotis, A. Spilker, S. Kandels-Lewis, I.Vernos, and T. Surrey. "A kinesin-like motor inhibits microtubule dynamic instability". Science, vol. 303, no. 5663, pp. 1519-1522, 2004
5. H. H. Loong, and W. Yeo. "Microtubule-targeting agents in oncology, and therapeutic potential in hepatocellular carcinoma". OncoTargets andTherapy, vol. 7, pp. 575-585, 2014
6. K. Klute, E. Nackos, S. Tasaki, D. P. Nguyen, N. H. Bander, and S. T. Tagawa. "Microtubule inhibitor-based antibody-drug conjugates for cancer therapy". OncoTargets andTherapy, vol. 7, pp. 2227-2236, 2014
7. M. Kavallaris,N.M.Verrills, and B. T. Hill. "Anticancer therapy with novel tubulin-interacting drugs". Drug Resistance Updates, vol. 4, no. 6, pp. 392-401, 2001
8. K. Katayama, K. Noguchi, and Y. Sugimoto. "Regulations of P-Glycoprotein/ABCB1/MDR1 in human cancer cells". New Journal of Science, vol. 2014, Article ID 476974, 10 pages, 2014
9. M. Kavallaris. "Microtubules, and resistance to tubulin-binding agents". Nature Reviews Cancer, vol. 10, no. 3, pp. 194-204, 2010
10. C. D. Katsetos, M. M. Herman, and S. J. Mörk. "Class III betatubulin in human development, and cancer". Cell Motility, and the Cytoskeleton, vol. 55, no. 2, pp. 77-96, 2003
11. M. Kavallaris, A. S. Tait, B. J.Walsh, et al. "Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells". Cancer Research, vol. 61, no. 15, pp. 5803-5809, 2001
12. J. J. Field, A. Kanakkanthara, and J. H. Miller. "Microtubuletargeting agents are clinically successful due to bothmitotic, and interphase impairment of microtubule function". Bioorganic, and Medicinal Chemistry, vol. 22, no. 18, pp. 5050-5059, 2014
13. Y.-M. Liu, H.-L. Chen, H.-Y. Lee, and J.-P. Liou. "Tubulin inhibitors: a patent review". Expert Opinion on Therapeutic Patents, vol. 24, no. 1, pp. 69-88, 2014
14. M.Moudi, R. Go, C. Y. S. Yien, and M. Nazre. "Vinca alkaloids". International Journal of Preventive Medicine, vol. 4, no. 11, pp. 1231-1235, 2013
15. R. K. Gregory, and I. E. Smith. "Vinorelbine-a clinical review". British Journal of Cancer, vol. 82, no. 12, pp. 1907-1913, 2000
16. S. Vallo, M. Michaelis, F. Rothweiler, et al. "Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics". Translational Oncology, vol. 8, no. 3, pp. 210-216, 2015
17. E. Mukhtar, V. M. Adhami, and H. Mukhtar. "Targeting microtubules by natural agents for cancer therapy". Molecular Cancer Therapeutics, vol. 13, no. 2, pp. 275-284, 2014
18. G. V. Subbaraju, T. Golakoti, G. M. L. Patterson, and R. E. Moore. "Three new cryptophycins from Nostoc sp. GSV 224". Journal of Natural Products, vol. 60, no. 3, pp. 302-305, 1997
19. C.Weiss, B. Sammet, andN. Sewald. "Recent approaches for the synthesis of modified cryptophycins". Natural Product Reports, vol. 30, no. 7, pp. 924-940, 2013
20. C. D. Smith, and X. Zhang. "Mechanism of action of cryptophycin. Interaction with the Vinca alkaloid domain of tubulin". Journal of Biological Chemistry, vol. 271, no. 11, pp. 6192-6198, 1996
21. S. L. Mooberry, L. Busquets, and G. Tien. "Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent". International Journal of Cancer, vol. 73, no. 3, pp. 440-448, 1997
22. D. Panda, V. Ananthnarayan, G. Larson, C. Shih, M. A. Jordan, and L.Wilson. "Interaction of the antitumor compound cryptophycin-52 with tubulin". Biochemistry, vol. 39, no. 46, pp. 14121-14127, 2000
23. C. Shih, and B. A. Teicher. "Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides". Current Pharmaceutical Design, vol. 7, no. 13, pp. 1259-1276, 2001
24. K. L. Bolduc, S. D. Larsen, andD. H. Sherman. "Efficient, divergent synthesis of cryptophycin unit A analogues". Chemical Communications, vol. 48, no. 51, pp. 6414-6416, 2012
25. T. H. Corbett, F. A. Valeriote, L. Demchik, et al. "Preclinical anticancer activity of cryptophycin-8". Journal of Experimental Therapeutics, and Oncology, vol. 1, no. 2, pp. 95-108, 1996
26. C. Sessa, K.Weigang-Köhler,O. Pagani, et al. "Phase I, and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule". European Journal of Cancer, vol. 38, no. 18, pp. 2388-2396, 2002
27. C. Dumontet, and M. A. Jordan. "Microtubule-binding agents: a dynamic field of cancer therapeutics". Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 790-803, 2010
28. G. D'Agostino, J. Del Campo, B. Mellado, et al. "A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer". International Journal of Gynecological Cancer, vol. 16, no. 1, pp. 71-76, 2006
29. R. S. Al-Awar, T. H. Corbett, J. E. Ray, et al. "Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity,"Molecular CancerTherapeutics, vol. 3, no. 9, pp. 1061-1067, 2004
30. M. M. Wagner, D. C. Paul, C. Shih, M. A. Jordan, L. Wilson, and D. C.Williams. "In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines". Cancer Chemotherapy, and Pharmacology, vol. 43, no. 2, pp. 115-125, 1999
31. J. P. Stevenson, W. Sun, M. Gallagher, et al. "Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1, and 8 schedule every 21 days". Clinical Cancer Research, vol. 8, no. 8, pp. 2524-2529, 2002
32. M. J. Edelman,D. R. Gandara, P.Hausner, et al. "Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer". Lung Cancer, vol. 39, no. 2, pp. 197-199, 2003
33. T. Corbett, L. Polin, P. LoRusso, et al. "In Vivo methods for screening, and preclinical testing". in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, pp. 99-123, Springer, Berlin, Germany, 2004
34. J. Liang, R. E. Moore, E. D. Moher, et al. "Cryptophycins-309, 249, and other cryptophycin analogs: preclinical efficacy studies with mouse, and human tumors". Investigational New Drugs, vol. 23, no. 3, pp. 213-224, 2005
35. K. Menon, E. Alvarez, P. Forler, et al. "Antitumor activity of cryptophycins: effect of infusion time, and combination studies". Cancer Chemotherapy, and Pharmacology, vol. 46,no. 2, pp. 142-149, 2000
36. R. R. Boinpally, L. Polin, S.-L. Zhou, et al. "Pharmacokinetics, and tissue distribution of cryptophycin 52 (C-52) epoxide, and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors". Cancer Chemotherapy, and Pharmacology, vol. 52, no. 1, pp. 25-33, 2003
37. J. Griggs, J. C. Metcalfe, and R. Hesketh. "Targeting tumour vasculature: the development of combretastatin A4". The Lancet Oncology, vol. 2, no. 2, pp. 82-87, 2001
38. G. G. Dark, S. A. Hill, V. E. Prise, G. M. Tozer, G. R. Pettit, and D. J. Chaplin. "Combretastatin A-4, an agent that displays potent, and selective toxicity toward tumor vasculature". Cancer Research, vol. 57, no. 10, pp. 1829-1834, 1997
39. G. M. Tozer, C. Kanthou, C. S. Parkins, and S. A. Hill. "The biology of the combretastatins as tumour vascular targeting agents". International Journal of Experimental Pathology, vol. 83, no. 1, pp. 21-38, 2002
40. S. M. Nabha, R. M. Mohammad, M. H. Dandashi, et al. "Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation, and poly(ADP-ribose) polymerase cleavage". Clinical Cancer Research, vol. 8, no. 8, pp. 2735-2741, 2002
41. I. Vitale, A. Antoccia, C. Cenciarelli, et al. "Combretastatin CA-4, and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint, and caspase-3 activation in non-small cell lung cancer cells". Apoptosis, vol. 12, no. 1, pp. 155-166, 2007
42. D. E. Friesen, K. H. Barakat, V. Semenchenko, et al. "Discovery of small molecule inhibitors that interact with -tubulin". Chemical Biology, and Drug Design, vol. 79, no. 5, pp. 639-652, 2012
43. C. D. Katsetos, G. Reddy, E. Dráberová, et al. "Altered cellular distribution, and subcellular sorting of -tubulin in diffuse astrocytic gliomas, and human glioblastoma cell lines". Journal of Neuropathology, and Experimental Neurology, vol. 65, no. 5, pp. 465-477, 2006
44. V. Caracciolo, L. D'Agostino, E. Dráberová, et al. "Differential expression, and cellular distribution of gamma-tubulin, and betaIII-tubulin in medulloblastomas, and human medulloblastoma cell lines". Journal of Cellular Physiology, vol. 223, no. 2,pp. 519-529, 2010
45. N. F. Maounis, E. Dráberová, E. Mahera, et al. "Overexpression of -tubulin in non-small cell lung cancer". Histology, and Histopathology, vol. 27, no. 9, pp. 1183-1194, 2012
46. T. Liu, Y. Niu, Y. Yu, Y. Liu, and F. Zhang. "Increased -tubulin expression, and P164 promoter methylation occur together in preinvasive lesions, and carcinomas of the breast". Annals of Oncology, vol. 20, no. 3, pp. 441-448, 2009
47. M. M. Mita, L. Sargsyan, A. C. Mita, and M. Spear. "Vasculardisrupting agents in oncology". Expert Opinion on Investigational Drugs, vol. 22, no. 3, pp. 317-328, 2013
48. G. M. Tozer, V. E. Prise, J. Wilson, et al. "Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors, and normal tissues". Cancer Research, vol. 59, no. 7, pp. 1626-1634, 1999
49. W. Landuyt, O. Verdoes, D. O. Darius, et al. "Vascular targeting of solid tumoursa major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas". European Journal of Cancer, vol. 36,no. 14,pp. 1833-1843, 2000
50. D. J.Chaplin, and S. A.Hill. "Thedevelopment of combretastatin A4 phosphate as a vascular targeting agent". International Journal of Radiation Oncology Biology Physics, vol. 54, no. 5, pp. 1491-1496, 2002
51. D. A. Beauregard, S. A. Hill, D. J. Chaplin, and K. M. Brindle. "The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability". Cancer Research, vol. 61, no. 18, pp. 6811-6815, 2001
52. C. Kanthou, and G. M. Tozer. "The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton, and early membrane blebbing in human endothelial cells". Blood, vol. 99, no. 6, pp. 2060-2069, 2002
53. A.Hussain, M. Steimle, H.Hoppeler,O. Baum, and S. Egginton. "The vascular-disrupting agent combretastatin impairs splitting, and sprouting forms of physiological angiogenesis,"Microcirculation, vol. 19, no. 4, pp. 296-305, 2012
54. L. Vincent, P. Kermani, L. M. Young, et al. "Combretastatin A4 phosphate induces rapid regression of tumor neovessels, and growth through interference with vascular endothelialcadherin signaling". Journal of Clinical Investigation, vol. 115, no. 11, pp. 2992-3006, 2005
55. A. C. Brooks, C. Kanthou, I. H. Cook, et al. "The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro". Anticancer Research, vol. 23, no. 4, pp. 3199-3206, 2003
56. G. U. Dachs, A. J. Steele, C. Coralli, et al. "Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1, and gene expression". BMC Cancer, vol. 6, article 280, 2006
57. L. Li,A.M. Rojiani, andD.W. Siemann. "Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate, and conventional anticancer therapies in the treatment of Kaposi's sarcoma". Acta Oncologica, vol. 41, no. 1, pp. 91-97, 2002
58. S. A. Hill, D. J. Chaplin, G. Lewis, and G. M. Tozer. "Schedule dependence of combretastatin A4 phosphate in transplanted, and spontaneous tumour models". International Journal of Cancer, vol. 102, no. 1, pp. 70-74, 2002
59. M. R. Horsman, and R.Murata. "Combination of vascular targeting agents with thermal or radiation therapy". International Journal of Radiation Oncology Biology Physics, vol. 54, no. 5, pp. 1518-1523, 2002
60. K. J. Lankester, R. J.Maxwell, R. B. Pedley, et al. "Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down". International Journal of Oncology, vol. 30, no. 2, pp. 453-460, 2007
61. H.Wildiers, B. Ahmed, G. Guetens, et al. "Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence". European Journal of Cancer, vol. 40, no. 2, pp. 284-290, 2004
62. S. L. Young, and D. J. Chaplin. "Combretastatin A4 phosphate: Background, and current clinical status". Expert Opinion on Investigational Drugs, vol. 13, no. 9, pp. 1171-1182, 2004
63. J. H. Bilenker, K. T. Flaherty, M. Rosen, et al. "Phase I trial of combretastatin A-4 phosphate with carboplatin". Clinical Cancer Research, vol. 11, no. 4, pp. 1527-1533, 2005
64. M. M. Cooney, T. Radivoyevitch, A. Dowlati, et al. "Cardiovascular safety profile of combretastatin a4 phosphate in a singledose phase I study in patients with advanced cancer". Clinical Cancer Research, vol. 10, no. 1, part 1, pp. 96-100, 2004
65. D. W. Siemann, D. J. Chaplin, and P. A. Walicke. "A review, and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)". Expert Opinion on Investigational Drugs, vol. 18, no. 2, pp. 189-197, 2009
66. R. Granata, L. D. Locati, and L. Licitra. "Fosbretabulin for the treatment of anaplastic thyroid cancer". Future Oncology, vol. 10, no. 13, pp. 2015-2021, 2014
67. A. Dowlati, K. Robertson, M. Cooney, et al. "A phase I pharmacokinetic, and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer". Cancer Research, vol. 62, no. 12, pp. 3408-3416, 2002
68. H. L. Anderson, J. T. Yap, M. P. Miller, A. Robbins, T. Jones, and P. M. Price. "Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate". Journal of Clinical Oncology, vol. 21, no. 15, pp. 2823-2830, 2003
69. G. J. S. Rustin, S. M. Galbraith, H. Anderson, et al. "Phase I clinical trial of weekly combretastatin A4 phosphate: clinical, and pharmacokinetic results". Journal of Clinical Oncology, vol. 21, no. 15, pp. 2815-2822, 2003
70. J. P. Stevenson, M. Rosen, W. Sun, et al. "Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow". Journal of Clinical Oncology, vol. 21, no. 23, pp. 4428-4438, 2003
71. R. Nallamothu, G. C. Wood, M. F. Kiani, B. M. Moore, F. P. Horton, and L. A. Thoma. "A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading, and in vitro release studies". PDA Journal of Pharmaceutical Science, and Technology, vol. 60, no. 3, pp. 144-155, 2006
72. J. A. Sosa, R. Elisei, B. Jarzab, et al. "Randomized safety, and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma,"Thyroid, vol. 24,no. 2, pp. 232-240, 2014
73. G. Korpanty, E. Smyth, and D. N. Carney. "Update on antiangiogenic therapy in non-small cell lung cancer: arewemaking progress?" Journal of Thoracic Disease, vol. 3, no. 1, pp. 19-29, 2011
74. J. Hua, Y. Sheng, K. G. Pinney, et al. "Oxi4503, a novel vascular targeting agent: effects on blood flow, and antitumor activity in comparison to combretastatin A-4 phosphate". Anticancer Research, vol. 23, no. 2, pp. 1433-1440, 2003
75. Y. Sheng, J. Hua, K. G. Pinney, et al. "Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis". International Journal of Cancer, vol. 111, no. 4, pp. 604-610, 2004
76. K. Staflin, S. Järnum, J. Hua, G. Honeth, P. Kannisto, and M. Lindvall. "Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin, and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma". International Journal of Gynecological Cancer, vol. 16, no. 4, pp. 1557-1564, 2006
77. I. G. Kirwan, P. M. Loadman, D. J. Swaine, et al. "Comparative preclinical pharmacokinetic, and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate, and A1 phosphate". Clinical Cancer Research, vol. 10, no. 4, pp. 1446-1453, 2004
78. D. M. Patterson, M. Zweifel, M. R. Middleton, et al. "Phase I clinical, and pharmacokinetic evaluation of the vasculardisrupting agent OXi4503 in patients with advanced solid tumors". Clinical Cancer Research, vol. 18, no. 5, pp. 1415-1425, 2012
79. J. Cummings, M. Zweifel, N. Smith, et al. "Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial". British Journal of Cancer, vol. 106, no. 11, pp. 1766-1771, 2012
80. S.Kumar, S.Mehndiratta,K.Nepali, et al. "Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors". Organic, and Medicinal Chemistry Letters, vol. 3, no. 1, article 3, 2013
81. S. Zheng, Q. Zhong, M. Mottamal, et al. "Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents". Journal ofMedicinal Chemistry, vol. 57, no. 8, pp. 3369-3381, 2014
82. K. Hori, S. Saito, Y. Sato, and K. Kubota. "Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect". Medical Science Monitor, vol. 7, no. 1, pp. 26-33, 2001
83. A. Delmonte, and C. Sessa. "AVE8062: a new combretastatin derivative vascular disrupting agent". Expert Opinion on Investigational Drugs, vol. 18, no. 10, pp. 1541-1548, 2009
84. K. Hori, and S. Saito. "Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis". British Journal of Cancer, vol. 89, no. 7, pp. 1334-1344, 2003
85. Y. Morinaga, Y. Suga, S. Ehara, K. Harada, Y. Nihei, and M. Suzuki. "Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine, and human tumors in vivo,"Cancer Science, vol. 94,no. 2, pp.200-204,2003
86. J. Y. Blay, Z. Pápai, A. W. Tolcher, et al. "Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline, and ifosfamide chemotherapy: a randomised, double-blind, placebocontrolled, phase 3 trial". The Lancet Oncology, vol. 16, no. 5, pp. 531-540, 2015
87. J. Poncet. "The dolastatins, a family of promising antineoplastic agents". Current Pharmaceutical Design, vol. 5, no. 3, pp. 139-162, 1999
88. F. Erik, and S. Jayaram. "The dolastatins". in Anticancer Agents from Natural Products, pp. 263-290, CRC Press, 2nd edition, 2011
89. L. M. Krug, V. A.Miller,G. P. Kalemkerian, et al. "Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer". Annals of Oncology, vol. 11, no. 2, pp. 227-228, 2000
90. K. Margolin, J. Longmate, T. W. Synold, et al. "Dolastatin-10 in metastatic melanoma: a phase II, and pharmokinetic trial of the California Cancer Consortium". Investigational New Drugs, vol. 19, no. 4, pp. 335-340, 2001
91. E. D. Saad, E. H. Kraut, P. M. Hoff, et al. "Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer". American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 25, no. 5, pp. 451-453, 2002
92. M. A. Hoffman, J. A. Blessing, and S. S. Lentz. "A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study". Gynecologic Oncology, vol. 89, no. 1, pp. 95-98, 2003
93. U. Vaishampayan, M. Glode, W. Du, et al. "Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma". Clinical Cancer Research, vol. 6, no. 11, pp. 4205-4208, 2000
94. E. A. Perez, D. W. Hillman, P. A. Fishkin, et al. "Phase II trial of dolastatin-10 in patients with advanced breast cancer". Investigational New Drugs, vol. 23, no. 3, pp. 257-261, 2005
95. H. L. Kindler, P. K. Tothy, R. Wolff, et al. "Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers". Investigational New Drugs, vol. 23, no. 5, pp. 489-493, 2005
96. M. Von Mehren, S. P. Balcerzak, A. S. Kraft, et al. "Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas". Sarcoma, vol. 8, no. 4, pp. 107-111, 2004
97. T. L. Simmons, E. Andrianasolo, K. McPhail, P. Flatt, and W. H. Gerwick. "Marine natural products as anticancer drugs". Molecular CancerTherapeutics, vol. 4, no. 2, pp. 333-342, 2005
98. J. Watanabe, T. Natsume, N. Fujio, K. Miyasaka, and M. Kobayashi. "Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent". Apoptosis, vol. 5, no. 4, pp. 345-353, 2000
99. P. Schöffski, B.Thate, G. Beutel, et al. "Phase I, and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer". Annals of Oncology, vol. 15, no. 4, pp. 671-679, 2004
100. M. J. A. De Jonge, A. vanderGaast, A. S. T. Planting, et al. "Phase I, and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1, and 8 of a 3-week cycle in patients with advanced solid tumors". Clinical Cancer Research, vol. 11, no. 10, pp. 3806-3813, 2005
101. K. Tamura, K.Nakagawa, T. Kurata, et al. "Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1, and 8 in 3-week courses". Cancer Chemotherapy, and Pharmacology, vol. 60,no. 2, pp. 285-293, 2007
102. A. Greystoke, S. Blagden, A. L. Thomas, et al. "A phase I study of intravenous TZT-1027 administered on day 1, and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours". Annals of Oncology, vol. 17, no. 8, pp. 1313-1319, 2006
103. J. Horti, E. Juhasz, Z.Monostori, K.Maeda, S. Eckhardt, and I. Bodrogi. "Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer". Cancer Chemotherapy, and Pharmacology, vol. 62, no. 1, pp. 173-180, 2008
104. S. Patel, M. L. Keohan, M. W. Saif, et al. "Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomaswith prior exposure to anthracycline-based chemotherapy". Cancer, vol. 107, no. 12, pp. 2881-2887, 2006
105. G. J. Riely, S. Gadgeel, I. Rothman, et al. "A phase 2 study of TZT-1027, administered weekly to patients with advanced nonsmall cell lung cancer following treatment with platinum-based chemotherapy". Lung Cancer, vol. 55, no. 2, pp. 181-185, 2007
106. Z. Cruz-Monserrate, J. T. Mullaney, P. G. Harran, G. R. Pettit, and E. Hamel. "Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography". European Journal of Biochemistry, vol. 270, no. 18, pp. 3822-3828, 2003
107. K. G. Steube, D. Grunicke, T. Pietsch, S.M. Gignac, G. R. Pettit, and H. G. Drexler. "Dolastatin 10, and dolastatin 15: effects of two natural peptides on growth, and differentiation of leukemia cells". Leukemia, vol. 6, no. 10, pp. 1048-1053, 1992
108. M. A. Ali, R. Rosati, G. R. Pettit, and G. P. Kalemkerian. "Dolastatin 15 induces apoptosis, and BCL-2 phosphorylation in small cell lung cancer cell lines". Anticancer Research, vol. 18,no. 2, pp. 1021-1026, 1998
109. M. Sato, M. Sagawa, T. Nakazato, Y. Ikeda, and M. Kizaki. "A natural peptide, dolastatin 15, induces G2/M cell cycle arrest, and apoptosis of human multiple myeloma cells". International Journal of Oncology, vol. 30, no. 6, pp. 1453-1459, 2007
110. R. L. Piekarz, R. Frye, M. Turner, et al. "Phase II multiinstitutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma". Journal of Clinical Oncology, vol. 27, no. 32, pp. 5410-5417, 2009
111. S. E. Bates, R. Eisch, A. Ling, et al. "Romidepsin in peripheral, and cutaneousT-cell lymphoma: mechanistic implications from clinical, and correlative data". British Journal of Haematology, vol. 170, no. 1, pp. 96-109, 2015
112. M. De Arruda, C. A. Cocchiaro, C. M. Nelson, et al. "LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules, and inhibits mitosis". Cancer Research, vol. 55,no. 14,pp. 3085-3092, 1995
113. M. A. Jordan, D. Walker, M. De Arruda, T. Barlozzari, and D. Panda. "Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action". Biochemistry, vol. 37, no. 50, pp. 17571-17578, 1998
114. M. A. Villalona-Calero, S. D. Baker, L. Hammond, et al. "Phase I, and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solidmalignancies". Journal of Clinical Oncology, vol. 16, no. 8, pp. 2770-2779, 1998
115. K. Mross, W. E. Berdel, H. H. Fiebig, R. Velagapudi, I. M. Von Broen, and C.Unger. "Clinical, and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group, and Arbeitsgruppe Pharmakologie in Der Onkologie und Haematologie (APOH) Group of the German Cancer Society". Annals ofOncology, vol. 9, no. 12, pp. 1323-1330, 1998
116. J. G. Supko, T. J. Lynch, J.W. Clark, et al. "A phase I clinical, and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion". Cancer Chemotherapy, and Pharmacology, vol. 46,no. 4, pp. 319-328, 2000
117. J. Smyth, M. E. Boneterre, J. Schellens, et al. "Activity of the dolastatin analogue, LU103793, in malignant melanoma". Annals of Oncology, vol. 12, no. 4, pp. 509-511, 2001
118. P. Kerbrat, V. Dieras, N. Pavlidis, A. Ravaud, J.Wanders, and P. Fumoleau. "Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer". European Journal of Cancer, vol. 39, no. 3, pp. 317-320, 2003
119. R. S. Marks, D. L. Graham, J. A. Sloan, et al. "A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer". American Journal of Clinical Oncology, vol. 26, no. 4, pp. 336-337, 2003
120. K. K. Rasila, and C. Verschraegen. "Tasidotin HCI genzyme". Current Opinion in Investigational Drugs, vol. 6, no. 6, pp. 631-638, 2005
121. R. Bai, M. C. Edler, P. L. Bonate, et al. "Intracellular activation, and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity,"Molecular Pharmacology, vol. 75, no. 1, pp. 218-226, 2009
122. A. Ray, T. Okouneva, T. Manna, et al. "Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651), and its major metabolite tasidotin Ccarboxylate". Cancer Research, vol. 67,no. 8, pp. 3767-3776, 2007
123. V. Garg, W. Zhang, P. Gidwani, M. Kim, and E. A. Kolb. "Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma". Clinical Cancer Research, vol. 13, no. 18, part 1, pp. 5446-5454, 2007
124. S. Ebbinghaus, E. Rubin, E. Hersh, et al. "A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors". Clinical Cancer Research, vol. 11, no. 21, pp. 7807-7816, 2005
125. C. Cunningham, L. J. Appleman, M. Kirvan-Visovatti, et al. "Phase I, and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors". Clinical Cancer Research, vol. 11, no. 21, pp. 7825-7833, 2005
126. A. C. Mita, L. A. Hammond, P. L. Bonate, et al. "Phase I, and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors". Clinical Cancer Research, vol. 12, no. 17, pp. 5207-5215, 2006
127. H. R. Hendriks, J. Plowman, D. P. Berger, et al. "Preclinical antitumour activity, and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent". Annals of Oncology, vol. 3, no. 9, pp. 755-763, 1992
128. A. E. Prota, K. Bargsten, J. F. Diaz, et al. "A new tubulinbinding site, and pharmacophore for microtubule-destabilizing anticancer drugs". Proceedings of the National Academy of Sciences of theUnited States ofAmerica, vol. 111, no. 38, pp. 13817-13821, 2014
129. T. Tsuruo, T. Oh-hara, H. Iida, et al. "Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human, and murine tumor cells, and the vincristine-resistant sublines". Cancer Research, vol. 46, no. 1, pp. 381-385, 1986
130. D. Bissett, M. A. Graham, A. Setanoians, et al. "Phase I, and pharmacokinetic study of rhizoxin". Cancer Research, vol. 52, no. 10, pp. 2894-2898, 1992
131. D. J. Kerr, G. J. Rustin, S. B. Kaye, et al. "Phase II trials of rhizoxin in advanced ovarian, colorectal, and renal cancer". British Journal of Cancer, vol. 72, no. 5, pp. 1267-1269, 1995
132. A. R. Hanauske, G. Catimel, S. Aamdal, et al. "Phase II clinical trials with rhizoxin in breast cancer andmelanoma.TheEORTC early clinical trials group". British Journal of Cancer, vol. 73, no. 3, pp. 397-399, 1996
133. J. Verweij, J.Wanders, T. Gil, et al. "Phase II study of rhizoxin in squamous cell head, and neck cancer". British Journal of Cancer, vol. 73, no. 3, pp. 400-402, 1996
134. S. Kaplan, A. R. Hanauske, N. Pavlidis, et al. "Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group". British Journal of Cancer, vol. 73, no. 3, pp. 403-405, 1996
135. H. L.McLeod, L. S.Murray, J.Wanders, et al. "Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology, and molecular mechanisms (PAMM) groups". British Journal of Cancer, vol. 74, no. 12, pp. 1944-1948, 1996
136. A. W. Tolcher, C. Aylesworth, J. Rizzo, et al. "A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors". Annals of Oncology, vol. 11, no. 3, pp. 333-338, 2000
137. G. Bacher, B. Nickel, P. Emig, et al. "D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy towardmultidrug-resistant tumor cells, and lacks neurotoxicity". Cancer Research, vol. 61, no. 1, pp. 392-399, 2001
138. A. Wienecke, and G. Bacher. "Indibulin, a novel microtubule inhibitor, discriminates betweenmature neuronal, and nonneuronal tubulin". Cancer Research, vol. 69, no. 1, pp. 171-177, 2009
139. H. Ito, T. Kanzawa, S. Kondo, and Y. Kondo. "Microtubule inhibitorD-24851 induces p53-independent apoptotic cell death in malignant glioma cells through Bcl-2 phosphorylation, and Bax translocation". International Journal of Oncology, vol. 26, no. 3, pp. 589-596, 2005
140. E. Stokvis, L. G. A. H. Nan-Offeringa, M. Ouwehand, et al. "Quantitative analysis of D-24851, a novel anticancer agent, in human plasma, and urine by liquid chromatography coupled with tandem mass spectrometry". Rapid Communications in Mass Spectrometry, vol. 18, no. 13, pp. 1465-1471, 2004
141. I. E. L. M. Kuppens, P. O. Witteveen, M. Schot, et al. "Phase I dose-finding, and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors". Investigational New Drugs, vol. 25, no. 3, pp. 227-235, 2007
142. T.-H. Huang, S.-J. Chiu, P.-H. Chiang, et al. "Antiproliferative effects of N-heterocyclic indolyl glyoxylamide derivatives on human lung cancer cells". Anticancer Research, vol. 31, no. 10, pp. 3407-3415, 2011
143. V. K. W. Wong, P. Chiu, S. S. M. Chung, et al. "Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype, and exhibits antitumor activity in vivo". Clinical Cancer Research, vol. 11, no. 16, pp. 6002-6011, 2005
144. X. Gong, M. Wang, S.-I. Tashiro, S. Onodera, and T. Ikejima. "Involvement of JNK-initiated p53 accumulation, and phosphorylation of p53 in pseudolaric acid B induced cell death". Experimental, and Molecular Medicine, vol. 38, no. 4, pp. 428-434, 2006
145. W.-F. Tan, X.-W. Zhang, M.-H. Li, et al. "Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect". European Journal of Pharmacology, vol. 499, no. 3, pp. 219-228, 2004
146. M.-H. Li, Z.-H. Miao, W.-F. Tan, et al. "Pseudolaric acid B inhibits angiogenesis, and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation". Clinical Cancer Research, vol. 10, no. 24, pp. 8266-8274, 2004
147. Y.-G. Tong, X.-W. Zhang, M.-Y. Geng, et al. "Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin". Molecular Pharmacology, vol. 69, no. 4, pp. 1226-1233, 2006
148. Q. Sun, and Y. Li. "The inhibitory effect of pseudolaric acid B on gastric cancer, and multidrug resistance via Cox-2/PKC-/P-gp pathway". PLoS ONE, vol. 9, no. 9,Article ID e107830, 2014
149. F. Yu, K. Li, S. Chen, Y. Liu, and Y. Li. "Pseudolaric acid B circumvents multidrug resistance phenotype in human gastric cancer SGC7901/ADR cells by downregulating Cox-2, and P-gp expression". Cell Biochemistry, and Biophysics, vol. 71, no. 1, pp. 119-126, 2015
150. H. J. Jung, J. S. Shim, H. B. Lee, et al. "Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro, and in vivo". Biochemical, and Biophysical Research Communications, vol. 353, no. 2, pp. 376-380, 2007
151. A. Kiselyov, K. V. Balakin, S. E. Tkachenko, N. Savchuk, and A. V. Ivachtchenko. "Recent progress in discovery, and development of antimitotic agents". Anti-Cancer Agents in Medicinal Chemistry, vol. 7, no. 2, pp. 189-208, 2007
152. C. De Ines, D. Leynadier, I. Barasoain, et al. "Inhibition of microtubules, and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863 ". Cancer Research, vol. 54, no. 1, pp. 75-84, 1994
153. K. E.Hook, S. A. Przybranowski, andW. R. Leopold. "Cellular transport of CI-980". Investigational New Drugs, vol. 14, no. 4, pp. 341-347, 1996
154. N. T. Sklarin, C. D. Lathia, L. Benson, et al. "A phase I trial, and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors". Investigational New Drugs, vol. 15, no. 3, pp. 235-246, 1997
155. C. A. Meyers, A. P. Kudelka, C. A. Conrad, C. K. Gelke, W. Grove, and R. Pazdur. "Neurotoxicity of CI-980, a novelmitotic inhibitor". Clinical Cancer Research, vol. 3, no. 3, pp. 419-422, 1997
156. M. L. Bernstein, S. Baruchel, S. Devine, et al. "Phase I, and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study". Journal of PediatricHematology/Oncology, vol. 21,no. 6, pp.494-500, 1999
157. E. K. Rowinsky, G. S. Long,D.A.Noe, et al. "Phase I, and pharmacological study of CI-980, a novel synthetic antimicrotubule agent". Clinical Cancer Research, vol. 3, no. 3, pp. 401-407, 1997
158. R. Pazdur, C. Meyers, E. Diaz-Canton, et al. "Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity". American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 20, no. 6, pp. 573-576, 1997
159. J. P. Thomas, T. Moore, E. H. Kraut, S. P. Balcerzak, S. Galloway, and D. D. Vandre. "A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study". Cancer Investigation, vol. 20, no. 2, pp. 192-198, 2002
160. A. P. Kudelka, A. Hasenburg, C. F. Verschraegen, et al. "Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma". Anti-Cancer Drugs, vol. 9, no. 5, pp. 405-409, 1998
161. B. Shan, J. C.Medina, E. Santha, et al. "Selective, covalent modification of -tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors". Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 10, pp. 5686-5691, 1999
162. S. M. Rubenstein, V. Baichwal, H. Beckmann, et al. "Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo, and show a decreased ability to cross the blood brain barrier". Journal of Medicinal Chemistry, vol. 44, no. 22, pp. 3599-3605, 2001
163. R. C. Donehower, G. Schwartz, A. C. Wolf, et al. "Phase I, and pharmacokinetic study of T138067 administered as a weekly 3-hour infusion". Clinical Cancer Research, vol. 6, pp. 4578s-4579s, 2000
164. G. Schwartz, E. K. Rowinsky, P. O'Dwyer, et al. "Phase I, and pharmacokinetic study of T138067, a synthetic microtubule depolymerizing agent, administered as a 3-hour infusion daily x 5 every 3 weeks". Clinical Cancer Research, vol. 6, pp. 4579s-4579s, 2000
165. S. Kirby, S. Z. Gertler, W. Mason, et al. "Phase 2 study of T138067-sodium in patients with malignant glioma: trial of the National Cancer Institute of Canada Clinical Trials Group". Neuro-Oncology, vol. 7, no. 2, pp. 183-188, 2005
166. J. D. Berlin, A. Venook, E. Bergsland, M. Rothenberg, A. C. Lockhart, and L. Rosen. "Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma". Clinical Colorectal Cancer, vol. 7, no. 1, pp. 44-47, 2008
167. K. A. Gelmon, K. Belanger, D. Soulieres, et al. "A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical TrialsGroup (NCIC-CTG) IND130". InvestigationalNewDrugs, vol. 23, no. 5, pp. 445-453, 2005
168. K. Yoshimatsu, A. Yamaguchi, H. Yoshino, N. Koyanagi, and K. Kitoh. "Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin". Cancer Research, vol. 57, no. 15, pp. 3208-3213, 1997
169. Y. Funahashi, N. Koyanagi, and K. Kitoh. "Effect of E7010 on liver metastasis, and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor". Cancer Chemotherapy, and Pharmacology, vol. 47, no. 2, pp. 179-184, 2001
170. Y. Iwamoto, K. Nishio, H. Fukumoto, K. Yoshimatsu, M. Yamakido, and N. Saijo. "Preferential binding of E7010 to murine 3-tubulin, and decreased 3-tubulin in E7010-resistant cell lines". Japanese Journal of Cancer Research, vol. 89, no. 9, pp. 954-962, 1998
171. K. Hayakawa, T. Tashiro, K. Sato, et al. "Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats: 17) testicular toxicity of e7010, a sulfonamide tubulin polymerization inhibitor". Journal of Toxicological Sciences, vol. 25, pp. 173-178, 2000
172. Y. Nihei, M. Suzuki,A.Okano, et al. "Evaluation of antivascular, and antimitotic effects of tubulin binding agents in solid tumor therapy". Japanese Journal of Cancer Research, vol. 90, no. 12, pp. 1387-1395, 1999
173. K. Yamamoto, K.Noda, A. Yoshimura,M. Fukuoka, K. Furuse, and H. Niitani. "Phase I study of E7010". Cancer Chemotherapy, and Pharmacology, vol. 42, no. 2, pp. 127-134, 1998
174. K. W. L. Yee, A. Hagey, S. Verstovsek, et al. "Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies". Clinical Cancer Research, vol. 11, no. 18, pp. 6615-6624, 2005
175. E. Fox, J. M. Maris, B. C. Widemann, et al. "A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors". Clinical Cancer Research, vol. 14, no. 4, pp. 1111-1115, 2008
176. A. M. Mauer, E. E.W. Cohen, P. C. Ma, et al. "Aphase II study of ABT-751 in patients with advanced non-small cell lung cancer". Journal ofThoracic Oncology, vol. 3, no. 6, pp. 631-636, 2008
177. J. Michels, S. L. Ellard, L. Le, et al. "A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer". Annals of Oncology, vol. 21, no. 2, pp. 305-311, 2010
178. C. M. Rudin, A. Mauer, M. Smakal, et al. "Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer". Journal of ClinicalOncology, vol. 29, no. 8, pp. 1075-1082, 2011
179. T. Ma, A. D. Fuld, J. R. Rigas, et al. "A phase i trial, and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients". Chemotherapy, vol. 58, no. 4, pp. 321-329, 2012
180. M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggon, and A. T. McPhail. "Plant antitumor agents. VI. The isolation, and structure of taxol, a novel antileukemic, and antitumor agent from Taxus brevifolia". Journal of the American Chemical Society, vol. 93, no. 9, pp. 2325-2327, 1971
181. M. Kavallaris, D. Y.-S. Kuo, C. A. Burkhart, et al. "Taxolresistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes". The Journal of Clinical Investigation, vol. 100, no. 5, pp. 1282-1293, 1997
182. J. A. McCarroll, P. P. Gan, M. Liu, and M. Kavallaris. "BetaIIItubulin is a multifunctional protein involved in drug sensitivity, and tumorigenesis in non-small cell lung cancer". Cancer Research, vol. 70, no. 12, pp. 4995-5003, 2010
183. P. P. Gan, J. A.McCarroll, S. T. Po'Uha,K.Kamath,M. A. Jordan, and M. Kavallaris. "Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of III-tubulin". Molecular CancerTherapeutics, vol. 9, no. 5, pp. 1339-1348, 2010
184. A. L. Parker, M. Kavallaris, and J. A. McCarroll. "Microtubules, and their role in cellular stress in cancer". Frontiers in Oncology, vol. 4, article 153, 2014
185. G. Raspaglio, F. Filippetti, S. Prislei, et al. "Hypoxia induces class III beta-tubulin gene expression by HIF-1 binding to its 3' flanking region". Gene, vol. 409, no. 1-2, pp. 100-108, 2008
186. M. De Donato, M. Mariani, L. Petrella, et al. "Class III betatubulin, and the cytoskeletal gateway for drug resistance in ovarian cancer". Journal of Cellular Physiology, vol. 227, no. 3, pp. 1034-1041, 2012
187. I. Ojima, S. Chakravarty, T. Inoue, et al. "A common pharmacophore for cytotoxic natural products that stabilize microtubules". Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 8, pp. 4256-4261, 1999
188. M. St. George, A. T. Ayoub, A. Banerjee, et al. "Designing, and testing of novel taxanes to probe the highly complex mechanisms by which taxanes bind to microtubules, and cause cytotoxicity to cancer cells". PLoS ONE, vol. 10, no. 6, Article ID e0129168, 2015
189. G.Höfle,N. Bedorf,H. Steinmetz,D. Schomburg, K.Gerth, and H. Reichenbach. "Epothilone A, and B-novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution". Angewandte Chemie, vol. 35, no. 13-14, pp. 1567-1569, 1996
190. M.Wartmann, and K.-H. Altmann. "The biology, and medicinal chemistry of epothilones". Current Medicinal Chemistry: Anti-Cancer Agents, vol. 2, no. 1, pp. 123-148, 2002
191. K.-H.Altmann,G. Bold, G. Caravatti, A. Flörsheimer, V. Guagnano, and M. Wartmann. "Synthesis, and biological evaluation of highly potent analogues of epothilones B, and D". Bioorganic, and Medicinal Chemistry Letters, vol. 10, no. 24, pp. 2765-2768, 2000
192. D. M. Bollag, P. A. McQueney, J. Zhu, et al. "Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action". Cancer Research, vol. 55, no. 11, pp. 2325-2333, 1995
193. C.-P. H. Yang, P. Verdier-Pinard, F. Wang, et al. "A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence". Molecular Cancer Therapeutics, vol. 4, no. 6, pp. 987-995, 2005
194. J. K. Peterson, C. Tucker, E. Favours, et al. "In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models". Clinical Cancer Research, vol. 11, part 1, no. 19, pp. 6950-6958, 2005
195. C. F. Brogdon, F. Y. Lee, and R. M. Canetta. "Development of other microtubule-stabilizer families: the epothilones, and their derivatives". Anticancer Drugs, vol. 25, no. 5, pp. 599-609, 2014
196. J. M. G. Larkin, and S. B.Kaye. "Epothilones in the treatment of cancer". Expert Opinion on Investigational Drugs, vol. 15, no. 6, pp. 691-702, 2006
197. K. De Geest, J. A. Blessing, R. T. Morris, et al. "Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum-, and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study". Journal of Clinical Oncology, vol. 28, no. 1, pp. 149-153, 2010
198. S. L. Mooberry, G. Tien, A. H. Hernandez, A. Plubrukarn, and B. S.Davidson. "Laulimalide, and isolaulimalide, newpaclitaxellike microtubule-stabilizing agents". Cancer Research, vol. 59, no. 3, pp. 653-660, 1999
199. D. E. Pryor, A. O'Brate, G. Bilcer, et al. "The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel, and epothilones, and may not require its epoxide moiety for activity". Biochemistry, vol. 41, no. 29, pp. 9109-9115, 2002
200. C. D. Churchill, M. Klobukowski, and J. A. Tuszynski. "The unique binding mode of laulimalide to two tubulin protofilaments". Chemical Biology & Drug Design, vol. 86, no. 2, pp. 190-199, 2015
201. H. Lu, J.Murtagh, and E. L. Schwartz. "The microtubule binding drug laulimalide inhibits vascular endothelial growth factorinduced human endothelial cell migration, and is synergistic when combined with docetaxel (taxotere)". Molecular Pharmacology, vol. 69, no. 4, pp. 1207-1215, 2006
202. P. A. Wender, M. K. Hilinski, N. Soldermann, and S. L. Mooberry. "Total synthesis, and biological evaluation of 11-desmethyllaulimalide, a highly potent simplified laulimalide analogue". Organic Letters, vol. 8, no. 7, pp. 1507-1510, 2006
203. A. E. Prota, K. Bargsten, P. T.Northcote, et al. "Structural basis of microtubule stabilization by laulimalide, and peloruside A". Angewandte Chemie, vol. 53, no. 6, pp. 1621-1625, 2014
204. C. Madiraju, M. C. Edler, E. Hamel, et al. "Tubulin assembly, taxoid site binding, and cellular effects of the microtubulestabilizing agent dictyostatin". Biochemistry, vol. 44, no. 45, pp. 15053-15063, 2005
205. L. L. Vollmer, M. Jiménez, D. P. Camarco, et al. "A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells, and antiangiogenic activity in zebrafish embryos". Molecular Cancer Therapeutics, vol. 10, no. 6, pp. 994-1006, 2011
206. K. R. Brunden, N. M. Gardner, M. J. James, et al. "MT-stabilizer, dictyostatin, exhibits prolonged brain retention, and activity: potential therapeutic implications". ACS Medicinal Chemistry Letters, vol. 4, no. 9, pp. 886-889, 2013
207. T. Lindel, P. R. Jensen,W. Fenical, et al. "ChemInform abstract: eleutherobin, a new cytotoxin that mimics paclitaxel (taxol) by stabilizing microtubules". ChemInform, vol. 28, no. 51, 2010
208. B.H. Long, J. M. Carboni, A. J.Wasserman, et al. "Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol)". Cancer Research, vol. 58, no. 6, pp. 1111-1115, 1998
209. E. Hamel, B. W. Day, J. H. Miller, et al. "Synergistic effects of pelorusideAand laulimalide with taxoid site drugs, but not with each other, on tubulin assembly". Molecular Pharmacology, vol. 70, no. 5, pp. 1555-1564, 2006
210. Y. Nakao, S. Yoshida, S. Matsunaga, and N. Fusetani. "(Z)-sarcodictyin A, a newhighly cytotoxic diterpenoid fromthe soft coral Bellonella albiflora". Journal of Natural Products, vol. 66, no. 4, pp. 524-527, 2003
211. A. L. Risinger, F. J. Giles, and S. L. Mooberry. "Microtubule dynamics as a target in oncology". Cancer Treatment Reviews, vol. 35, no. 3, pp. 255-261, 2009
212. R. Kaur, G. Kaur, R. K. Gill, R. Soni, and J. Bariwal. "Recent developments in tubulin polymerization inhibitors: an overview". European Journal ofMedicinal Chemistry, vol. 87, pp. 89-124, 2014
213. Z. Liu, P. Xu, T. Wu, and W. Zeng. "Microtubule-targeting anticancer agents from marine natural substance". Anti-Cancer Agents in Medicinal Chemistry, vol. 14, no. 3, pp. 409-417, 2014
214. J. Cortes, and J. Baselga. "Targeting the microtubules in breast cancer beyond taxanes: the epothilones". Oncologist, vol. 12, no. 3, pp. 271-280, 2007
215. L. Vahdat. "Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms". Oncologist, vol. 13, no. 3, pp. 214-221, 2008